FibroBiologics, Inc. Common Stock (FBLG)vsModerna Inc (MRNA)
FBLG
FibroBiologics, Inc. Common Stock
$1.24
+2.90%
HEALTHCARE · Cap: $9.67M
MRNA
Moderna Inc
$190.01
+0.57%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
FBLG leads profitability with a 0.0% profit margin vs -141.4%. FBLG earns a higher WallStSmart Score of 23/100 (F).
FBLG
Avoid23
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FBLG.
Margin of Safety
+69.9%
Fair Value
$134.59
Current Price
$190.01
$55.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 11.2x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : FBLG
The strongest argument for FBLG centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : FBLG
The primary concerns for FBLG are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
FBLG profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
FBLG carries more volatility with a beta of 1.68 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
FBLG generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
FBLG scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
FibroBiologics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology, specifically targeting degenerative diseases and spinal disorders. The company's robust intellectual property portfolio and commitment to clinical excellence position it favorably within the rapidly evolving cellular therapy market. By fostering strategic partnerships and enhancing research initiatives, FibroBiologics aims to transform patient care and improve clinical outcomes with its cutting-edge therapeutic solutions.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?